Affiliation:
1. Petrozavodsk State University
2. Institute of Biology of the Karelian Research Centre of the Russian Academy of Sciences
Abstract
The goal. To determine the value of the triglyceride glucose index (TGI) for the diagnosis of insulin resistance (IR) in early forms of non-alcoholic fatty liver disease (NAFLD).Materials and methods. 99 patients with NAFLD were examined: 38 (38.4%) with liver steatosis (LS) and 61 (61.6%) with steatohepatitis (SH). TGI was determined by the formula — In [fasting TG (mg / dl) × fasting glucose (mg / dl) / 2], patients with LS and SH were divided into quartiles (Q1-Q4) by increasing TGI levels with an assessment of liver tests, insulin levels (“Insulin TEST System”, Monobind Inc., USA), HOMA-IR, fragments of cytokeratin-18 (FCK-18) ("TPS ELISA, Biotech”, Sweden) and TNF-α (“Human TNFα Platinum” ELISA, eBioscience, Austria).Results. In patients with LS with a TGI increase from Q1 to Q4, HOMA-IR increased from 1.12 ± 0.48 to 6.02 ± 3.15 (p <0.05), a direct relationship was found between these indicators — r = 0.52 (p = 0.03). TGI also correlated with waist circumference — r = 0.81 (p = 0.01), cholesterol — r = 0.51 (p = 0.002), alkaline phosphatase — r = 0.41 (p = 0.02). In patients with SH, from Q1 to Q4, HOMA-IR increased from 3.15 ± 1.8 to 6.2 ± 3.04 (p <0.05), but there was no significant correlation between HOMA-IR and TGI. The levels of FCK-18 increased from Q1 to Q4-139.82 ± 72.45 to 359.75 ± 189.03 U / L (p <0.05) and TNF-α — from 6.38 ± 1.25 pg / ml up to 7.75 ± 1.09 pg / ml (p <0.05). There was a connection between TGI and the level of a marker of hepatocyte apoptosis — FCK-18 — r = 0.43 (p = 0.004).Conclusion. In liver steatosis, TGI has demonstrated its diagnostic role as a surrogate marker of insulin resistance, correlating with HOMA-IR. In steatohepatitis, TGI reflected the degree of hepatocytic apoptosis, correlating with fragments of cytokeratin-18.
Publisher
LLC Global Media Technology
Subject
Gastroenterology,Hepatology
Reference16 articles.
1. Lazebnik L.B., Radchenko V. G., Dzhadhav S. N., Sitkin S. I., Seliverstov P. V. Systemic inflammation and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(5):29-41. (In Russ.) doi: 10.31146/1682-8658-ecg-165-5-29-41.
2. Mantovani A, Byrne ChD, Bonora E and Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018;41(2):372-382.
3. Simental-Mendia L. E., Rodriguez-Moran, M. & Guerrero-Romero, F.The Product of Fasting Glucose and Triglycerides as Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects. Metab Syndr Relat Disord. 2008;6 (4):299-304.
4. Roytberg G.E., Dorosh Zh.V., Sharkhun O. O., Ushakova T. I., Trubino E. A. New metabolic index use potentialities in evaluation of insulin resistance in clinical practice. Rational Pharmacotherapy in Cardiology. 2014;10(3):264-274. doi: 10.20996/1819-6446-201410-3-264-274.
5. Ruyatkina L.A., Ruyatkin D. S., Iskhakova I. S., Shcherb akova L. V. Possibilities of assessing insulin resistance as the metabolic syndrome clustering in postmenopausal women. Medical advice. 2019. No. 4, pp. 88-93. (in Russ.)